SLNO Logo

Soleno Therapeutics, Inc. (SLNO) 

NASDAQ
Market Cap
$2.21B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
716 of 776
Rank in Industry
392 of 433

Largest Insider Buys in Sector

SLNO Stock Price History Chart

SLNO Stock Performance

About Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and …

Insider Activity of Soleno Therapeutics, Inc.

Over the last 12 months, insiders at Soleno Therapeutics, Inc. have bought $0 and sold $129.34M worth of Soleno Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Soleno Therapeutics, Inc. have bought $13.51M and sold $27.09M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 250,000 shares for transaction amount of $5M was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2023‑09‑28.

List of Insider Buy and Sell Transactions, Soleno Therapeutics, Inc.

2024-10-01SaleCHIEF EXECUTIVE OFFICER
21,633
0.0564%
$49.43$1.07M+8.52%
2024-10-01SaleCHIEF FINANCIAL OFFICER
8,077
0.0211%
$49.43$399,241+8.52%
2024-10-01SaleSEE REMARKS
3,108
0.0081%
$49.43$153,627+8.52%
2024-10-01SaleSEE REMARKS
3,108
0.0081%
$49.43$153,627+8.52%
2024-08-29Sale10 percent owner
100,000
0.2609%
$47.22$4.72M+10.82%
2024-08-29SaleCHIEF EXECUTIVE OFFICER
58,391
0.1525%
$47.28$2.76M+10.82%
2024-08-29SaleCHIEF FINANCIAL OFFICER
6,870
0.0179%
$47.28$324,845+10.82%
2024-08-29SaleSEE REMARKS
5,435
0.0142%
$47.28$256,992+10.82%
2024-08-29SaleSEE REMARKS
5,435
0.0142%
$47.28$256,992+10.82%
2024-08-28Sale10 percent owner
425,000
1.101%
$47.35$20.12M+9.20%
2024-08-28SaleCHIEF EXECUTIVE OFFICER
56,613
0.1474%
$47.58$2.69M+9.20%
2024-08-28SaleCHIEF FINANCIAL OFFICER
6,661
0.0173%
$47.58$316,938+9.20%
2024-08-28SaleSEE REMARKS
5,270
0.0137%
$47.58$250,753+9.20%
2024-08-28SaleSEE REMARKS
5,270
0.0137%
$47.58$250,753+9.20%
2024-08-27Sale10 percent owner
500,000
1.2782%
$48.73$24.36M+4.16%
2024-08-06SaleCHIEF EXECUTIVE OFFICER
69,131
0.1847%
$45.46$3.14M+7.44%
2024-08-06SaleCHIEF FINANCIAL OFFICER
8,134
0.0217%
$45.46$369,736+7.44%
2024-08-06SaleSEE REMARKS
5,977
0.016%
$45.46$271,689+7.44%
2024-08-06SaleSEE REMARKS
5,957
0.0159%
$45.46$270,780+7.44%
2024-08-05SaleCHIEF EXECUTIVE OFFICER
58,213
0.1616%
$45.77$2.66M+10.22%

Insider Historical Profitability

78.58%
Anish BhatnagarCHIEF EXECUTIVE OFFICER
719553
1.8511%
$56.79413<0.0001%
Mackaness James HCHIEF FINANCIAL OFFICER
119172
0.3066%
$56.79311<0.0001%
Abingworth LLP10 percent owner
18022602
46.3644%
$56.7930+8.21%
Sinclair Andrew
18022602
46.3644%
$56.7940+23.93%
ENGLEMAN EDGAR
4033540
10.3766%
$56.7920+22.67%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Vivo Capital$360.29M24.288.42M0%+$031.38
The Carlyle Group$173.12M11.744.07M+42.47%+$51.61M7.43
Perceptive Advisors$131.59M8.873.07M0%+$00.09
Janus Henderson$122.7M8.282.87M+13.74%+$14.83M0.06
Nantahala Capital Management Llc$103.16M6.952.41M-15.61%-$19.09M4.8
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.